Original Paper

Parasitology Research

, Volume 90, Issue 2, pp S71-S76

Fosmidomycin for the treatment of malaria

  • Jochen WiesnerAffiliated withJomaa Pharmaka GmbH, Frankfurter Strasse 50, 35392 Gießen, Germany Email author 
  • , Steffen BorrmannAffiliated withDepartment of Parasitology, Institute of Tropical Medicine, University of Tübingen, 72074 Tübingen, Germany
  • , Hassan JomaaAffiliated withJomaa Pharmaka GmbH, Frankfurter Strasse 50, 35392 Gießen, Germany

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract.

In malaria parasites, isoprenoids are synthesised by the mevalonate independent 1-deoxy-D-xylulose 5-phosphate (DOXP) pathway. Fosmidomycin, a natural antibiotic originally developed for the treatment of bacterial infections, represents an inhibitor of DOXP reductoisomerase, an essential enzyme of this pathway. In recent clinical studies it was shown that fosmidomycin is effective in curing uncomplicated Plasmodium falciparum malaria in humans. The treatment was well tolerated and resulted in a fast parasite and fever clearance. However, the high rate of recrudescence precludes the use of fosmidomycin as a monotherapy. In drug combination studies, synergy of fosmidomycin with clindamycin was observed. Clinical studies with a fosmidomycin-clindamycin combination are currently ongoing.